Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Mitoprotective therapy prevents rapid, strain-dependent mitochondrial dysfunction after articular cartilage injury.

Bartell LR, Fortier LA, Bonassar LJ, Szeto HH, Cohen I, Delco ML.

J Orthop Res. 2019 Dec 16. doi: 10.1002/jor.24567. [Epub ahead of print]

PMID:
31840828
2.

Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle.

Montalvo RN, Doerr V, Min K, Szeto HH, Smuder AJ.

Am J Physiol Regul Integr Comp Physiol. 2020 Feb 1;318(2):R227-R233. doi: 10.1152/ajpregu.00299.2019. Epub 2019 Nov 27.

PMID:
31774307
3.

ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.

Ducasa GM, Mitrofanova A, Mallela SK, Liu X, Molina J, Sloan A, Pedigo CE, Ge M, Santos JV, Hernandez Y, Kim JJ, Maugeais C, Mendez AJ, Nair V, Kretzler M, Burke GW, Nelson RG, Ishimoto Y, Inagi R, Banerjee S, Liu S, Szeto HH, Merscher S, Fontanesi F, Fornoni A.

J Clin Invest. 2019 Jul 22;129(8):3387-3400. doi: 10.1172/JCI125316. eCollection 2019 Jul 22.

4.

Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.

Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, Wang L, Bammler TK, Moore RJ, White CC, Kavanagh TJ, Voss JG, Szeto HH, Rabinovitch PS, MacCoss MJ, Qian WJ, Marcinek DJ.

Free Radic Biol Med. 2019 Apr;134:268-281. doi: 10.1016/j.freeradbiomed.2018.12.031. Epub 2018 Dec 28.

PMID:
30597195
5.

Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases.

Szeto HH.

Protein Pept Lett. 2018;25(12):1108-1123. doi: 10.2174/0929866525666181101105209. Review.

PMID:
30381054
6.

Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging.

Szeto HH, Liu S.

Arch Biochem Biophys. 2018 Dec 15;660:137-148. doi: 10.1016/j.abb.2018.10.013. Epub 2018 Oct 23. Review.

PMID:
30359579
7.

Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice.

Toyama S, Shimoyama N, Szeto HH, Schiller PW, Shimoyama M.

ACS Chem Neurosci. 2018 Jul 18;9(7):1566-1571. doi: 10.1021/acschemneuro.8b00013. Epub 2018 Apr 18.

8.

Crosstalk between autophagy and oxidative stress regulates proteolysis in the diaphragm during mechanical ventilation.

Smuder AJ, Sollanek KJ, Nelson WB, Min K, Talbert EE, Kavazis AN, Hudson MB, Sandri M, Szeto HH, Powers SK.

Free Radic Biol Med. 2018 Feb 1;115:179-190. doi: 10.1016/j.freeradbiomed.2017.11.025. Epub 2017 Nov 29.

9.

Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD.

Szeto HH.

J Am Soc Nephrol. 2017 Oct;28(10):2856-2865. doi: 10.1681/ASN.2017030247. Epub 2017 Aug 4. Review.

10.

The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.

Sweetwyne MT, Pippin JW, Eng DG, Hudkins KL, Chiao YA, Campbell MD, Marcinek DJ, Alpers CE, Szeto HH, Rabinovitch PS, Shankland SJ.

Kidney Int. 2017 May;91(5):1126-1145. doi: 10.1016/j.kint.2016.10.036. Epub 2017 Jan 4.

11.

Mitochondria Protection after Acute Ischemia Prevents Prolonged Upregulation of IL-1╬▓ and IL-18 and Arrests CKD.

Szeto HH, Liu S, Soong Y, Seshan SV, Cohen-Gould L, Manichev V, Feldman LC, Gustafsson T.

J Am Soc Nephrol. 2017 May;28(5):1437-1449. doi: 10.1681/ASN.2016070761. Epub 2016 Nov 23.

12.

Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury.

Szeto HH, Liu S, Soong Y, Alam N, Prusky GT, Seshan SV.

Kidney Int. 2016 Nov;90(5):997-1011. doi: 10.1016/j.kint.2016.06.013. Epub 2016 Aug 9.

PMID:
27519664
13.

In vivo high-resolution magic angle spinning magnetic and electron paramagnetic resonance spectroscopic analysis of mitochondria-targeted peptide in Drosophila melanogaster with trauma-induced thoracic injury.

Constantinou C, Apidianakis Y, Psychogios N, Righi V, Mindrinos MN, Khan N, Swartz HM, Szeto HH, Tompkins RG, Rahme LG, Tzika AA.

Int J Mol Med. 2016 Feb;37(2):299-308. doi: 10.3892/ijmm.2015.2426. Epub 2015 Dec 8.

14.

Partial Support Ventilation and Mitochondrial-Targeted Antioxidants Protect against Ventilator-Induced Decreases in Diaphragm Muscle Protein Synthesis.

Hudson MB, Smuder AJ, Nelson WB, Wiggs MP, Shimkus KL, Fluckey JD, Szeto HH, Powers SK.

PLoS One. 2015 Sep 11;10(9):e0137693. doi: 10.1371/journal.pone.0137693. eCollection 2015.

15.

Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia.

Birk AV, Chao WM, Liu S, Soong Y, Szeto HH.

Biochim Biophys Acta. 2015 Oct;1847(10):1075-84. doi: 10.1016/j.bbabio.2015.06.006. Epub 2015 Jun 10.

16.

A mitochondrial therapeutic reverses visual decline in mouse models of diabetes.

Alam NM, Mills WC 4th, Wong AA, Douglas RM, Szeto HH, Prusky GT.

Dis Model Mech. 2015 Jul 1;8(7):701-10. doi: 10.1242/dmm.020248. Epub 2015 Apr 23.

17.

Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.

Min K, Kwon OS, Smuder AJ, Wiggs MP, Sollanek KJ, Christou DD, Yoo JK, Hwang MH, Szeto HH, Kavazis AN, Powers SK.

J Physiol. 2015 Apr 15;593(8):2017-36. doi: 10.1113/jphysiol.2014.286518. Epub 2015 Feb 23.

18.

Mitochondrial pharmacology: its future is now.

Szeto HH, James LP, Atkinson AJ.

Clin Pharmacol Ther. 2014 Dec;96(6):629-33. doi: 10.1038/clpt.2014.177.

PMID:
25399706
19.

Improving mitochondrial bioenergetics under ischemic conditions increases warm ischemia tolerance in the kidney.

Szeto HH, Liu S, Soong Y, Birk AV.

Am J Physiol Renal Physiol. 2015 Jan 1;308(1):F11-21. doi: 10.1152/ajprenal.00366.2014. Epub 2014 Oct 22.

20.

Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke.

Kim EH, Tolhurst AT, Szeto HH, Cho SH.

CNS Neurosci Ther. 2015 Apr;21(4):385-91. doi: 10.1111/cns.12326. Epub 2014 Sep 12.

21.

Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.

Szeto HH, Birk AV.

Clin Pharmacol Ther. 2014 Dec;96(6):672-83. doi: 10.1038/clpt.2014.174. Epub 2014 Sep 4. Review.

22.

Mitochondrial oxidative stress in aging and healthspan.

Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS.

Longev Healthspan. 2014 May 1;3:6. doi: 10.1186/2046-2395-3-6. eCollection 2014. Review.

23.

Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis.

Liu S, Soong Y, Seshan SV, Szeto HH.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F970-80. doi: 10.1152/ajprenal.00697.2013. Epub 2014 Feb 19.

24.

Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis.

Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH.

Br J Pharmacol. 2014 Apr;171(8):2017-28. doi: 10.1111/bph.12468.

25.

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Szeto HH.

Br J Pharmacol. 2014 Apr;171(8):2029-50. doi: 10.1111/bph.12461. Review.

26.

Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies.

Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M.

Anesthesiology. 2014 Feb;120(2):459-73. doi: 10.1097/01.anes.0000435634.34709.65.

PMID:
24064792
27.

Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.

Dai DF, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, Beyer RP, Crispin DA, Shulman NJ, Szeto HH, Tian R, MacCoss MJ, Rabinovitch PS.

Circ Heart Fail. 2013 Sep 1;6(5):1067-76. doi: 10.1161/CIRCHEARTFAILURE.113.000406. Epub 2013 Aug 9.

28.

The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.

Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH.

J Am Soc Nephrol. 2013 Jul;24(8):1250-61. doi: 10.1681/ASN.2012121216. Epub 2013 Jul 11.

29.

Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant.

Talbert EE, Smuder AJ, Min K, Kwon OS, Szeto HH, Powers SK.

J Appl Physiol (1985). 2013 Aug 15;115(4):529-38. doi: 10.1152/japplphysiol.00471.2013. Epub 2013 Jun 13.

30.

Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.

Siegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ.

Aging Cell. 2013 Oct;12(5):763-71. doi: 10.1111/acel.12102. Epub 2013 Jun 11.

31.

Mitochondria-targeted antioxidant promotes recovery of skeletal muscle mitochondrial function after burn trauma assessed by in vivo 31P nuclear magnetic resonance and electron paramagnetic resonance spectroscopy.

Righi V, Constantinou C, Mintzopoulos D, Khan N, Mupparaju SP, Rahme LG, Swartz HM, Szeto HH, Tompkins RG, Tzika AA.

FASEB J. 2013 Jun;27(6):2521-30. doi: 10.1096/fj.12-220764. Epub 2013 Mar 12.

32.

Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain.

Shimoyama M, Schiller PW, Shimoyama N, Toyama S, Szeto HH.

Chem Biol Drug Des. 2012 Nov;80(5):771-4. doi: 10.1111/cbdd.12003. Epub 2012 Sep 3.

33.

Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy.

Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH, Powers SK.

J Appl Physiol (1985). 2011 Nov;111(5):1459-66. doi: 10.1152/japplphysiol.00591.2011. Epub 2011 Aug 4.

34.

Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.

Szeto HH, Schiller PW.

Pharm Res. 2011 Nov;28(11):2669-79. doi: 10.1007/s11095-011-0476-8. Epub 2011 Jun 3. Review.

PMID:
21638136
35.

Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury.

Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, Zhao Z, Ganger M, Tow CY, Seshan SV.

J Am Soc Nephrol. 2011 Jun;22(6):1041-52. doi: 10.1681/ASN.2010080808. Epub 2011 May 5.

36.

Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness.

Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, Kavazis AN, Smuder AJ.

Crit Care Med. 2011 Jul;39(7):1749-59. doi: 10.1097/CCM.0b013e3182190b62.

37.

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.

Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B, Reddy PH.

J Alzheimers Dis. 2010;20 Suppl 2:S609-31. doi: 10.3233/JAD-2010-100564.

38.

Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF.

Antioxid Redox Signal. 2009 Sep;11(9):2095-104. doi: 10.1089/ARS.2009.2445.

39.

Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans.

Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD.

J Clin Invest. 2009 Mar;119(3):573-81. doi: 10.1172/JCI37048. Epub 2009 Feb 2.

40.

Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells.

Han Z, Varadharaj S, Giedt RJ, Zweier JL, Szeto HH, Alevriadou BR.

J Pharmacol Exp Ther. 2009 Apr;329(1):94-101. doi: 10.1124/jpet.108.145557. Epub 2009 Jan 8.

41.

Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.

Szeto HH.

Ann N Y Acad Sci. 2008 Dec;1147:112-21. doi: 10.1196/annals.1427.013. Review.

PMID:
19076436
42.

Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine.

Shimoyama M, Szeto HH, Schiller PW, Tagaito Y, Tokairin H, Eun Cm, Shimoyama N.

Pharmacology. 2009;83(1):33-7. doi: 10.1159/000167878. Epub 2008 Nov 6.

43.

A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction.

Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D.

Am J Physiol Renal Physiol. 2008 Nov;295(5):F1545-53. doi: 10.1152/ajprenal.00395.2007. Epub 2008 Sep 10.

44.

Antiviral activity of geneticin against bovine viral diarrhoea virus.

Birk AV, Dubovi EJ, Zhang X, Szeto HH.

Antivir Chem Chemother. 2008;19(1):33-40.

PMID:
18610556
45.

Cytoplasmic vacuolization responses to cytopathic bovine viral diarrhoea virus.

Birk AV, Dubovi EJ, Cohen-Gould L, Donis R, Szeto HH.

Virus Res. 2008 Mar;132(1-2):76-85. Epub 2007 Dec 3.

46.

Do mitochondriotropic antioxidants prevent chlorinative stress-induced mitochondrial and cellular injury?

Whiteman M, Spencer JP, Szeto HH, Armstrong JS.

Antioxid Redox Signal. 2008 Mar;10(3):641-50.

PMID:
18052717
47.

Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury.

Szeto HH.

Antioxid Redox Signal. 2008 Mar;10(3):601-19. Review.

PMID:
17999629
48.

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.

Endocrinology. 2007 Sep;148(9):4136-46. Epub 2007 May 10.

PMID:
17495006
49.

Potent mitochondria-targeted peptides reduce myocardial infarction in rats.

Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK.

Coron Artery Dis. 2007 May;18(3):215-20.

PMID:
17429296
50.

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.

J Med Chem. 2007 Feb 22;50(4):835-47.

PMID:
17300166

Supplemental Content

Loading ...
Support Center